Eric L Simpson
Overview
Explore the profile of Eric L Simpson including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
270
Citations
8418
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Paller A, Ramien M, Cork M, Simpson E, Lee L, Eichenfield L, et al.
Pediatr Dermatol
. 2024 Nov;
PMID: 39529307
Objective: To evaluate long-term infection rates in children aged 6 months to 5 years with moderate-to-severe atopic dermatitis (AD) treated with dupilumab. Methods: This was a post hoc analysis of...
12.
Paller A, Mendes-Bastos P, Siegfried E, Eichenfield L, Soong W, Prajapati V, et al.
JAMA Dermatol
. 2024 Oct;
160(12):1304-1313.
PMID: 39441580
Importance: The Measure Up 1, Measure Up 2, and AD Up studies demonstrated the efficacy and adverse events of upadacitinib through 52 weeks in adults and adolescents with atopic dermatitis...
13.
Paller A, Silverberg J, Simpson E, Cork M, Arkwright P, Chen Z, et al.
J Am Acad Dermatol
. 2024 Sep;
92(1):116-126.
PMID: 39349183
Background: Moderate-to-severe atopic dermatitis (AD) greatly impacts children/caregivers. Objective: Evaluate the impact of treatment with dupilumab on caregiver- and patient-reported AD symptoms and quality of life (QoL) in young children....
14.
Kenney H, Yoshida T, Berdyshev E, Calatroni A, Gill S, Simpson E, et al.
J Allergy Clin Immunol
. 2024 Sep;
155(2):479-490.
PMID: 39343173
Background: Atopic dermatitis (AD) is an inflammatory skin condition characterized by widely variable cutaneous Staphylococcus aureus abundance that contributes to disease severity and rapidly responds to type 2 immune blockade...
15.
Silverberg J, Gold L, Desai S, Golant A, DiRuggiero D, Fenske D, et al.
J Dermatolog Treat
. 2024 Sep;
35(1):2396382.
PMID: 39322226
Background: The decision to initiate advanced systemics in patients with atopic dermatitis (AD) is complex. Objectives: To explore disease burden and clinical characteristics of patients with moderate-to-severe AD and identify...
16.
Simpson E, Eichenfield L, Alonso-Llamazares J, Draelos Z, Ferris L, Forman S, et al.
JAMA Dermatol
. 2024 Sep;
160(11):1161-1170.
PMID: 39292443
Importance: Safe, effective, and well-tolerated topical treatment options available for long-term use in patients with atopic dermatitis (AD) are limited and associated with low adherence rates. Objective: To evaluate efficacy...
17.
Haag C, Alexis A, Aoki V, Bissonnette R, Blauvelt A, Chovatiya R, et al.
Br J Dermatol
. 2024 Sep;
192(1):135-143.
PMID: 39250758
Background: Janus kinase inhibitors (JAKi) have the potential to alter the landscape of atopic dermatitis (AD) management dramatically, owing to promising efficacy results from phase III trials and their rapid...
18.
Simpson E, Guttman-Yassky E, Pawlikowski J, Ghorayeb E, Ota T, Lebwohl M
Arch Dermatol Res
. 2024 Aug;
316(8):589.
PMID: 39214920
Bermekimab is a human-derived recombinant monoclonal antibody that exhibits immunoregulatory activity by specifically blocking interleukin-1α activity. Four phase 2 studies evaluated efficacy and safety of bermekimab in patients with moderate-to-severe...
19.
Diehl K, Barber C, Simpson E, Banh M, Cantu M, Price K, et al.
Dermatitis
. 2024 Aug;
PMID: 39109445
No abstract available.
20.
Bradshaw L, Wyatt L, Brown S, Haines R, Montgomery A, Perkin M, et al.
Health Technol Assess
. 2024 Jul;
28(29):1-116.
PMID: 39021147
Background: Atopic eczema is a common childhood skin problem linked with asthma, food allergy and allergic rhinitis that impairs quality of life. Objectives: To determine whether advising parents to apply...